Rocket Pharmaceuticals reports Q3 EPS (45c), consensus (52c)

Cash, cash equivalents and investments as of September 30, 2025, were $222.8 million. Rocket expects such resources, excluding any potential future proceeds from a Priority Review Voucher that may be granted upon FDA approval of KRESLADI(TM), will be sufficient to fund its operations into the second quarter of 2027. “During the third quarter, we maintained disciplined execution and sharpened our strategic focus on Rocket’s AAV cardiovascular gene therapy portfolio,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals (RCKT). “In under three months, we aligned with the FDA to resume the Phase 2 pivotal study of RP-A501 for Danon disease, an important milestone that underscores the FDA’s collaborative approach and recognition of the urgent need for innovative therapies in rare cardiovascular disorders. In parallel, we are advancing RP-A601 toward a pivotal Phase 2 study in PKP2-ACM and preparing RP-A701 for first-in-human evaluation in BAG3-DCM. Finally, the upcoming March PDUFA date for KRESLADI(TM) represents a significant near-term commercial milestone as we work to bring this potentially life-saving therapy to patients with severe LAD-I.”